1987
Developmental therapeutics and the acquired immunodeficiency syndrome.
DeVita V, Broder S, Fauci A, Kovacs J, Chabner B. Developmental therapeutics and the acquired immunodeficiency syndrome. Annals Of Internal Medicine 1987, 106: 568-81. PMID: 2435201, DOI: 10.7326/0003-4819-106-4-568.Peer-Reviewed Original ResearchConceptsHuman T-lymphotropic virus type IIIPotential screening targetsTreatment of AIDST4 subsetOverwhelming infectionImmunodeficiency syndromeOpportunistic infectionsDevelopmental therapeuticsImmune competenceAntiviral drugsViral DNA polymeraseScreening targetsType IIIInfectionAIDSViral integrationDrugsSpecific targetsEncouraging resultsPatientsSyndromeLymphocytes
1980
Cancer, the Curable Diseases
DeVita V, Kershner L. Cancer, the Curable Diseases. Journal Of The American Pharmacists Association 1980, 20: 16-22. PMID: 6155779, DOI: 10.1016/s0160-3450(15)32990-1.Peer-Reviewed Original Research
1976
A Phase I–II Trial of Multiple-Dose Polyriboinosinic-Polyribocytidylic Acid in Patients With Leukemia or Solid Tumors
Robinson R, DeVita V, Levy H, Baron S, Hubbard S, Levine A. A Phase I–II Trial of Multiple-Dose Polyriboinosinic-Polyribocytidylic Acid in Patients With Leukemia or Solid Tumors. Journal Of The National Cancer Institute 1976, 57: 599-602. PMID: 978771, DOI: 10.1093/jnci/57.3.599.Peer-Reviewed Original ResearchConceptsSolid tumorsSerum glutamic oxaloacetic transaminaseSerum glutamic pyruvic transaminaseSeparate drug trialsObjective tumor responseDetectable serum levelsRoute of administrationChronic myelogenous leukemiaLow serum concentrationsGlutamic oxaloacetic transaminaseGlutamic pyruvic transaminasePolyriboinosinic-polyribocytidylic acidPoly I-poly CInducers of interferonCoagulation abnormalitiesSerum levelsMultiple dosesSerum concentrationsTumor responseAcute leukemiaDrug trialsBlast crisisMyelogenous leukemiaTransient elevationDrug dose